Pfizer Outlicenses PARP Inhibitor To Clovis
Clovis Oncology will develop and commercialize a PARP inhibitor for solid tumors that was previously being developed by Pfizer.
Clovis Oncology will develop and commercialize a PARP inhibitor for solid tumors that was previously being developed by Pfizer.